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Human adenoviruses (HAdVs) encode for multifunctional non-coding virus-associated (VA) RNAs, which
function as powerful suppressors of the cellular interferon (IFN) and RNA interference (RNAi) systems. In
this study we tested the ability of various plant and animal virus encoded RNAi and IFN suppressor
proteins to functionally substitute for the HAdV-5 VA RNAI. Our results revealed that only the Vaccinia
virus (VACV) E3L protein was able to substitute for the HAdV-5 VA RNAI functions in virus-infected cells.
Interestingly, the E3L protein rescues the translational defect but does not stimulate viral capsid mRNA
accumulation observed with VA RNA. We further show that the E3L C-terminal region containing the
dsRNA-binding domain is needed to enhance VA RNAI mutant virus replication. Additionally, we show
that the HAdV-4 and HAdV-37 VA RNAI are more effective than the HAdV-5 VA RNAI in rescuing virus
replication.
& 2015 Elsevier Inc. All rights reserved.
Introduction
One of the fundamental pathways that a virus has to evade is
the host cell antiviral response. The ﬁrst line of antiviral defense
mounted by the host is carried out by the interferon (IFN) and/or
by the RNA interference (RNAi) systems. The antiviral IFN response
depends on the activation of a cellular IFN signaling cascade,
which triggers expression and activity of multiple interferon
stimulated genes including the double-stranded (ds) RNA-activ-
ated protein kinase (PKR) (Sadler and Williams, 2008). In its
enzymatically active form PKR phosphorylates the α subunit of
the essential translation initiation factor eIF2. Site-speciﬁc phos-
phorylation of eIF2α at serine 51 (Ser51) impairs the GDP-GTP
recycling of eIF2 and causes a global inhibition of translation
initiation, which would be detrimental for virus multiplication
(Garcia et al., 2006). In the case of RNAi, the antiviral defense is
initiated by viral double stranded RNA (dsRNA) replication inter-
mediates, which are processed by the Dicer enzyme into small
interfering RNAs (siRNAs). Subsequent incorporation of siRNAs
into the RNA-induced silencing complex (RISC) gives rise to the
activated RISC, which catalyzes viral RNA degradation and thereby
blocks virus ampliﬁcation (Voinnet, 2005). It is well established
that the RNAi system can block ampliﬁcation of multiple plant and
invertebrate viruses (Ding and Voinnet, 2007; Szittya and Burgyan,
2013). In contrast, mammalian cells rely primarily on the antiviral
IFN system to overcome virus infections. However, recent reports
have also provided evidence that the RNAi system can function as
an antiviral defense mechanism in mammalian cells (Li et al.,
2013; Maillard et al., 2013).
To bypass the RNAi-mediated antiviral response, plant viruses
encode for RNA silencing suppressor (RSS) proteins that target and
modulate the functions of different RNAi components. This is well
exempliﬁed in the case of the Tomato bushy stunt virus (TBSV) P19
protein, which in its dimeric form interacts and sequesters siRNA
duplexes from being incorporated into RISC (Danielson and
Pezacki, 2013). Likewise, a very high afﬁnity of the Rice hoja
blanca virus (RHBV) NS3 protein towards siRNA duplexes blocks
functional RISC assembly in plants (Hemmes et al., 2007).
Mammalian viruses encode for proteins that effectively antag-
onizes the IFN-induced antiviral response. Here the favorite target
of intervention is the PKR enzyme. During most virus infections
the latent PKR protein binds to dsRNA produced during virus
multiplication (Dauber and Wolff, 2009). This binding results in a
dimerization and autophosphorylation of the protein (Dey et al.,
2005). Consequently PKR becomes active as a protein kinase
phosphorylating the eIF2α substrate protein. To prevent the
activated PKR from blocking viral protein synthesis, many viruses
encode for proteins that have a suppressive effect on PKR activa-
tion/activity (Langland et al., 2006). For example, the Ebola virus
(EBOV) VP35, the Inﬂuenza A virus NS1, and the Vaccinia virus
(VACV) E3L proteins function as competitive dsRNA-binding pro-
teins, blocking PKR dimerization and consequently PKR activation
(Davies et al., 1993; Feng et al., 2007; Lu et al., 1995). In contrast,
the Hepatitis C virus E2 and the Human immunodeﬁciency virus-1
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(HIV-1) Tat proteins show homology to eIF2α and block the
activated PKR from phosphorylating its natural substrate (Brand
et al., 1997; Taylor et al., 1999). Interestingly, some of the PKR
suppressor proteins described above (VP35, E3L, Tat) can also
suppress the RNAi pathway in mammalian cells (Haasnoot et al.,
2007). They are therefore regarded as potential mammalian virus-
encoded RSS proteins (Bivalkar-Mehla et al., 2011).
In contrast to other mammalian viruses, human adenovirus
(HAdV) and Epstein-Barr virus encode for short, highly structured
non-coding RNAs that can counteract the host antiviral defense
system (Steitz et al., 2011). A majority of HAdV serotypes encode
for two virus-associated (VA) RNA genes, VA RNAI and VA RNAII.
Both VA RNAs accumulate at similar low levels during the early
phase of infection, whereas the VA RNAI becomes the predomi-
nant RNA expressed at the late phase of infection (Soderlund et al.,
1976). VA RNAI binds with a high afﬁnity to the PKR protein
thereby preventing PKR dimerization and activation (Katze et al.,
1987; Kitajewski et al., 1986a; McKenna et al., 2007). In contrast,
VA RNAII shows little or no activity in comparison to VA RNAI as
an RNA complementing HAdV growth (Ma and Mathews, 1993).
The VA RNAs have also been shown to interfere with the RNAi
system. For example, the VA RNAs act as competitive substrates
suppressing Dicer processing of exogenous dsRNA into siRNA in
HAdV-infected cells (Andersson et al., 2005). Also, VA RNAI blocks
nuclear export of the Dicer mRNA, thereby reducing Dicer protein
synthesis (Bennasser et al., 2011). Further, the VA RNAs are
processed by the Dicer enzyme into viral small RNAs, the so-
called mivaRNAs, and are efﬁciently incorporated into the RISC
(Aparicio et al., 2006; Kamel et al., 2014; Xu et al., 2007).
Collectively, these observations indicate that the VA RNAs may
act as HAdV-encoded RSS molecules by suppressing the function
of RNAi components in mammalian cells. Hence, the VA RNAs can
be considered as multifunctional non-coding RNAs inhibiting both
the IFN and the RNAi systems during lytic virus growth (Punga et
al., 2013).
It is well established that the VA RNAs, and particularly VA
RNAI is required to establish an efﬁcient lytic adenovirus life cycle
(Bhat and Thimmappaya, 1984; Fowlkes and Shenk, 1980;
Kitajewski et al., 1986b; Thimmappaya et al., 1982). It is clear that
the inhibitory effect of VA RNA on PKR activation is crucial for the
virus but the signiﬁcance of the suppressive effect of the VA RNAs
on the RNAi is still unresolved. Interestingly, whereas majority of
mammalian viruses have evolved proteins to counteract the host
cell antiviral defense response, HAdV has evolved non-coding
RNAs, the VA RNAs, to perform the same function(s).
Here we asked whether suppressor proteins encoded by other
animal and plant viruses could substitute for VA RNAI during a
lytic HAdV-5 infection. For this purpose we tested whether the
plant TBSV P19 and RHBV NS3 proteins or the animal EBOV VP35
and VACV E3L proteins could functionally substitute for HAdV-5
VA RNAI during a lytic adenovirus infection. The results show that
viral suppressor proteins, P19, NS3 and VP35, were unable to
rescue VA RNAI mutant dl705 virus growth. In contrast, the VACV
E3L protein partially rescued viral capsid protein synthesis and
virus multiplication. Further functional analysis showed that the
E3L C-terminal region containing the dsRNA-binding domain was
critical for the rescue phenotype. Finally, we show that the HAdV-
4 and HAdV-37 VA RNAI were more efﬁcient to complement VA
RNAI mutant virus replication compared to the native HAdV-5
VA RNAI.
Results
The VACV E3L protein can substitute for VA RNAI as an enhancer of
adenovirus late protein synthesis
To determine whether the VA RNAI function(s) can be sub-
stituted by viral suppressor proteins known to interfere with the
IFN and/or RNAi systems (Bivalkar-Mehla et al., 2011; Langland
et al., 2006), HEK293 cells were transfected with increasing
amounts of plasmids expressing Flag-epitope tagged TBSV P19,
RHBV NS3, VACV E3L or EBOV VP35 proteins. At 24 h post-
transfection (hpt) cells were infected with the VA RNAI deﬁcient,
dl705 virus (Bhat and Thimmappaya, 1984). After 22 h post-
infection (hpi) cells were 35S pulse-labeled for 2 h, proteins were
isolated and separated on SDS-PAGE followed by visualization of
viral capsid protein accumulation by western blot analysis or the
capsid protein synthesis by autoradiography (Fig. 1). We have
previously shown that co-transfection of plasmid expressing
simian adenovirus VA RNAI efﬁciently complement the VA RNAI
mutant virus phenotype (Larsson et al., 1986). Thus, as expected
cells transfected with the pHindB plasmid (expressing HAdV-2 VA
RNAI and VA RNAII) signiﬁcantly enhanced virus capsid protein
Fig. 1. The VACV E3L protein can substitute for VA RNAI as an enhancer of
adenovirus late protein synthesis. HEK293 cells were transfected with increasing
amounts (2 and 4 μg) of plasmids encoding Flag-tagged P19, NS3, E3L, VP35
proteins and HAdV-2 VA RNA encoding plasmid pHindB. Transfected cells were
further infected with VA RNAI deﬁcient, dl705 virus and metabolically labeled with
35S-methionine/cysteine mix. Total protein extracts were resolved on SDS-PAGE
and analyzed by western blotting (WB) and autoradiography (35S). Protein expres-
sion was detected using anti-capsid, anti-actin and anti-Flag antibodies. Hyphen (-)
indicates uninfected, control plasmid (pcDNA3.1) transfected sample, letter “E”
designates an empty, non-protein sample loaded lane on SDS-PAGE. Asterisk (n)
speciﬁes the migration of the viral capsid hexon protein. Black arrows specify the
migration of indicated Flag-tagged proteins. Label P19n indicates migration of the
potential P19 dimer protein. Relative quantiﬁcation of the 35S-labeled hexon
protein is shown below the image. The hexon protein 35S signal from the sample
infected solely with dl705 was set as 1.
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production in dl705-infected cells (Fig. 1, lanes 10 and 11). In
contrast, transient overexpression of the P19, NS3 or VP35 proteins
did not enhance capsid protein accumulation in dl705-infected
cells (Fig. 1, lanes 2–5 and 8 and 9). This failure to complement the
VA RNAI mutant phenotype was not due to a lack of expression of
the Flag epitope-tagged proteins (Fig. 1, middle panel). Interest-
ingly, overexpression of the VACV E3L protein stimulated the
accumulation and synthesis of the viral capsid proteins, although
not to the same level as pHindB co-transfection (Fig. 1, lanes 6 and
7 and 10 and 11). Quantiﬁcation of the 35S incorporation into the
hexon protein, which is the major viral capsid protein, indicated
that pHindB co-transfection enhanced hexon protein synthesis
approximately 3-fold better than the E3L protein.
To test whether the failure of the P19, NS3 and VP35 proteins to
enhance capsid protein accumulation could be due to a lack of
RNAi suppressor activity in HEK293 cells, we tested if the sup-
pressor proteins could relieve siRNA-mediated ﬁreﬂy luciferase
reporter gene silencing in the HEK293 cell line. In line with the
previous reports (Fabozzi et al., 2011; Liu et al., 2012; Schnettler
et al., 2008), the P19, NS3, and VP35 proteins enhanced ﬁreﬂy
luciferase expression (Supplementary Fig. 1A), whereas the
expression of the control renilla luciferase reporter gene was not
enhanced (Supplementary Fig. 1B). Notably, the E3L protein
elevated the expression of both reporter genes, suggesting that
this protein might have a more general effect on reporter gene
expression.
Taken together, our results indicate that the VACV E3L protein,
at least partially can rescue the translational defect of virus capsid
protein synthesis in dl705-infected HEK293 cells.
The E3L C-terminal region is required to complement the VA RNAI
mutant phenotype
The VACV E3L protein has a well-deﬁned modular structure
(Fig. 2A). The N-terminus of the protein contains a Z-DNA-binding
domain needed for speciﬁc DNA sequence interaction (Kwon and
Rich, 2005). Interestingly, the same domain has been shown to
interact and inhibit the PKR enzymatic activity in some experi-
mental systems (Romano et al., 1998; Thakur et al., 2014). The C-
terminus of the E3L protein exhibits dsRNA-binding capacity
(Chang and Jacobs, 1993). Mutating lysine 167 and arginine 168
(K167A/R168A) (hereafter referred as E3L(KRAA)) within this
domain severely impair the dsRNA-binding capacity of the E3L
protein (Ho and Shuman, 1996). Therefore, it became of interest to
assess, which functional domain of the E3L protein was required
for complementation of the dl705 mutant phenotype. For this
purpose HEK293 cells were transiently transfected with plasmids
encoding the E3L wild type or mutant proteins (Fig. 2A). After
24 hpt cells were infected with the dl705 virus. As a control, one
plate of cells was infected with the wild-type dl703 virus, which
expresses both VA RNAI and VA RNAII. At 22 hpi cells were 35S
pulse-labeled and total proteins separated on an SDS-PAGE. As
shown in Fig. 2B, co-transfection of a plasmid expressing the wild
type E3L(wt) protein (lane 2) or the HAdV-2 VA RNAs (pHindB,
lane 5) stimulated, as expected, capsid protein expression in
dl705-infected cells. Expression of the HAdV-2 VA RNAs stimu-
lated dl705 capsid protein expression almost to the same level as
was seen in dl703-infected cells (Fig. 2B, lanes 5 and 7), whereas
the E3L(wt) protein expression did not have such a drastic effect
on capsid protein levels (Fig. 2B, lanes 2 and 7). The E3L mutant
proteins either lacking the dsRNA-binding domain [E3L(1–100)] or
containing the double mutation disrupting the dsRNA-binding
activity [E3L(KRAA)], failed to enhance HAdV capsid protein
expression (Fig. 2B, lanes 3 and 4). Notably, expression levels of
the E3L(wt) and E3L(1–100) proteins were similar, whereas the
E3L(KRAA) protein showed reproducibly a low expression in
HEK293 cells (Fig. 2B, middle panel). Hence, failure of the E3L
(KRAA) protein to enhance viral capsid protein expression might
be due to reduced accumulation of this mutated E3L protein in
dl705-infected cells.
It is likely that E3L(wt), like the VA RNAs, stimulates HAdV
capsid protein expression by suppressing eIF2α phosphorylation.
To test this hypothesis the samples shown in Fig. 2B were probed
with antibodies recognizing phosphorylated eIF2α (P-Ser51) and
total eIF2α. As shown in Fig. 2C, transient overexpression of E3L
(wt), reduced eIF2α phosphorylation to the same level as did VA
RNA co-expression (pHindB) (lanes 1 and 4). However, E3L(wt) or
VA RNA overexpression did not reduce eIF2α phosphorylation to
the same level as was seen in wild-type dl703-infected cells
(Fig. 2C, lanes 1, 4, and 6). In agreement with the observed failure
to rescue capsid protein accumulation (Fig. 2B), transfection of
plasmids expressing the mutant proteins E3L(1–100) or E3L
(KRAA) did not affect the P-Ser51 signal strength (Fig. 2C, lanes
2 and 3).
The VACV E3L protein functionally substitutes for VA RNAI in new
virus progeny formation
A stimulatory effect on viral capsid protein synthesis does not
necessarily translate into an enhanced virus production. Therefore,
we tested whether substitution of VA RNAI with the E3L(wt)
protein also enhanced formation of infectious dl705 virus parti-
cles. For this experiment HEK293 cells were transiently transfected
with pHindB or plasmids encoding the E3L proteins shown in
Fig. 2A. Following 24 hpt cells were infected with the dl705 virus
and 40 hpi total cell lysates were titrated in 911 cells. The 911 cell
line is used as a standard cell line for the titration and propagation
of adenovirus (Fallaux et al., 1996). As shown in Fig. 3, transient
expression of the E3L(wt) protein stimulated infectious dl705 virus
production approximately 10-fold, whereas the E3L(1–100) or E3L
(KRAA) proteins failed to improve the virus titer. It is noteworthy
that the burst size of infectious virus in pHindB co-transfected
cells was approximately 7-fold higher compared to the virus yield
in E3L(wt) expressing cells. Taken together our results show that
the VACV E3L protein, at least partially substitutes for VA RNAI in
new adenovirus progeny formation. Further, our experiments
indicate that the E3L C-terminal region containing the dsRNA-
binding domain is required for this stimulatory effect on virus
production.
Adenovirus dl705 infection alters the subcellular distribution of E3L
Previous experiments have shown that the E3L protein loca-
lizes both to the cytoplasm and the nucleus in transfected HeLa
cells (Kwon and Rich, 2005). To determine the effect of HAdV
infection on the localization of the E3L protein we investigated the
subcellular distribution of the E3L(wt) protein at the late phase of
a dl705 infection. For this purpose HeLa cells were transiently
transfected with the plasmid encoding the Flag-tagged E3L(wt)
protein. Transfected cells were infected with dl705, and 24 hpi
cells were ﬁxed and immunostained with a monoclonal anti-Flag
antibody. As shown in Fig. 4A, the E3L(wt) protein showed both
nuclear and cytoplasmic localization in uninfected HeLa cells.
Interestingly, a dl705 infection resulted in an enhanced cytoplas-
mic staining of the E3L(wt) protein. This increase in cytoplasmic
accumulation was further conﬁrmed by a biochemical subcellular
fractionation experiment (Fig. 4B, lanes 2 and 5).
We have repeatedly noted that the total levels of the E3L(wt)
protein is higher in dl705-infected cells compared to uninfected cells
(Fig. 4B, lanes 1 and 4). To determine whether this alteration in protein
expression was due to changes in the E3L protein stability we tested
the effect of a proteasome inhibitor on E3L abundance and
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distribution. For this experiment, E3L transfected HeLa cells were
treated with the proteasome inhibitor MG132 followed by separation
into a cytoplasmic and a nuclear fractions (Fig. 4B). The biochemical
fractionation was efﬁcient as evidenced by the nuclear localization of
the lamin B1 protein and the cytoplasmic distribution of the GAPDH
protein, respectively. Similarly, the MG132 treatment resulted in the
expected stabilization of the c-Myc protein (Fig. 4B, lanes 1 and 7).
However, MG132 treatment did not enhance the E3L protein stability
in HeLa cells (Fig. 4B, lanes 1 and 7). Taken together, our results
indicate that the E3L(wt) protein has a preferred cytoplasmic localiza-
tion in dl705-infected cells.
E3L enhances adenovirus capsid protein synthesis by suppressing PKR
phosphorylation of eIF2α
The E3L(wt) protein reduced eIF2α Ser51 phosphorylation in
dl705-infected cells (Fig. 2C). However, the eIF2α Ser51 residue is
the target for phosphorylation by multiple protein kinases includ-
ing PKR, PERK, GCN2 and HI (Donnelly et al., 2013). Therefore, it
became of interest to determine whether the reduced eIF2α
phosphorylation in dl705-infected cells was due to E3L inhibition
of the PKR function. For this experiment, we took advantage of a
HeLa cell line where PKR expression has been reduced to less than
2% by a stable expression of a PKR speciﬁc shRNA (Zhang and
Samuel, 2007). The PKR knockdown (PKRkd) and control (PKRkd-
con) cell lines were transfected with E3L(wt) or pHindB plasmids
for 24 h followed by dl705 infection for an additional 24 h.
Similarly to the previous experiments (Figs. 1 and 2) E3L and VA
RNA (pHindB) expression enhanced viral capsid protein synthesis
also in PKRkd-con cells (Fig. 5A, lanes 6–8). However, viral capsid
proteins accumulated to much higher levels in PKRkd cells, in
agreement with the hypothesis that PKR has a negative effect on
dl705 virus growth (Fig. 5A, lanes 2–4). Quantiﬁcation of hexon
protein synthesis conﬁrmed that E3L(wt) and pHindB transfection
elevated viral capsid protein synthesis in PKR expressing (PKRkd-
con) but not in PKRkd cells (Fig. 5A). The same protein samples were
also used to detect eIF2α Ser51 phosphorylation. In line with our
previous data (Fig. 2), E3L(wt) or pHindB co-transfection reduced
the eIF2α P-Ser51 signal in PKRkd-con cells (Fig. 5B, lanes 6–8), but
not in PKRkd cells (Fig. 5B, lanes 2–4). Collectively, our data suggest
that E3L-mediated eIF2α hypophosphorylation is mainly due to an
inhibition of PKR activity in dl705-infected cells.
The E3L protein does not enhance viral late mRNA accumulation
Previous results have shown that the VA RNAs in addition to
enhancing mRNA translation, via a suppression of the PKR func-
tion, also increase cytoplasmic mRNA abundance (Strijker et al.,
Fig. 2. The E3L C-terminal region complements the VA RNAI mutant virus phenotype. (A) Schematic representation of the VACV E3L(wt), E3L(KRAA) and E3L(1-100) proteins
with their established Z-DNA- and dsRNA-binding domains. (B) E3L C-terminal region containing the dsRNA-binding domain is required to elevate HAdV capsid protein
levels. Transfected (4 μg of plasmid DNA) HEK293 cells were infected with dl705 virus and metabolically labeled with 35S-methionine/cysteine mix. Immunoblotting was
done with anti-capsid, anti-Flag and anti-actin antibodies. Asterisk (n) indicates the migration of the viral capsid hexon protein. Hyphen (-) indicates uninfected sample or a
sample transfected with an empty plasmid (pcDNA3.1). As the control, cells were also infected with wild type HAdV-5 (dl703) virus. (C) The E3L(wt) protein reduces eIF2α
Ser51 phosphorylation. The protein lysates from (B) were analyzed by western blotting using anti-eIF2α (Total) and anti-eIF2α (P-Ser51) antibodies. Relative accumulation of
P-Ser51 signal in total eIF2α protein pool (P-Ser51/Total) is shown. The P-Ser51/Total eIF2α ratio in dl705 only infected sample was set as 1.
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1989; Svensson and Akusjarvi, 1990). Our results show that
the E3L(wt) protein can enhance virus capsid protein synthesis
by interfering with the PKR function in dl705-infected cells
(Figs. 1 and 5). However, we have also repeatedly observed that
VA RNA expression promotes viral capsid protein accumulation
and new virus progeny formation signiﬁcantly better compared to
the E3L(wt) protein (Figs. 1–3). To determine whether the E3L(wt)
protein might lack the mRNA enhancer function ascribed to the VA
RNAs, we analyzed hexon mRNA accumulation under the same
experimental setup shown in Fig. 1. As shown in Fig. 6, transfec-
tion of the E3L(wt) protein expressing plasmid had only a marginal
effect on hexon mRNA accumulation in dl705-infected HEK293
cells, whereas VA RNA expression (pHindB) increased hexon
mRNA levels up to 4-fold.
Complementation of dl705 virus replication by serotype-speciﬁc VA
RNAI
The VA RNAs originating from different adenovirus serotypes
display considerable variations in sequence and length, suggesting
that they might have serotype-speciﬁc functions in infected cells
(Ma and Mathews, 1993, 1996). Indeed, we showed recently that
the VA RNAs from HAdV-4, HAdV-5, HAdV-11 and HAdV-37 are
processed differently by the Dicer enzyme (Kamel et al., 2014). To
determine if the VA RNAs from different serotypes are functionally
redundant we tested whether VA RNAI from various serotypes
were equally efﬁcient in rescuing dl705 virus growth. For this
experiment HEK293 cells were transiently transfected with plas-
mids expressing VA RNAI from HAdV-4, HAdV-5, HAdV-12 and
HAdV-37, followed by dl705 virus infection. At 22 hpi cells were
35S pulse-labeled and protein lysates were separated on an SDS-
PAGE, followed by a visualization of viral capsid protein accumula-
tion by western blot analysis and capsid protein synthesis by
autoradiography. As shown in Fig. 7A, HAdV-4 and HAdV-37 VA
RNAI had a more robust impact on capsid protein accumulation
compared to the HAdV-2 VA RNAs (pHindB), HAdV-5 and HAdV-
12 VA RNAI. In fact, HAdV-4 and HAdV-37 VA RNAI appear to
complement the VA RNAI defect in dl705-infected cells more
efﬁciently compared to the native HAdV-5 VA RNAI (Fig. 7A, lanes
2, 3 and 5). Northern blot analysis from the same experimental
setup conﬁrmed that similar levels of the HAdV-4, HAdV-5, HAdV-
12 and HAdV-37 VA RNAI were expressed in the transfected
HEK293 cells (Fig. 7B).
The different effects of the serotype-speciﬁc VA RNAIs on viral
capsid protein accumulation might be due to a variation in their
impact on PKR-mediated eIF2α phosphorylation. To test this
hypothesis we analyzed the eIF2α P-Ser51 phosphorylation status
by western blotting in the same samples depicted in Fig. 7A. As
shown in Fig. 7C, HAdV-4 and HAdV-37 VA RNAI expression
reduced eIF2α P-Ser51 signal somewhat better compared to the
other serotype VA RNAIs (lanes 2–5).
To further conﬁrm that HAdV-4 and HAdV-37 VA RNAI are
effective in complementing dl705 virus growth, we measured
infectious dl705 virus particle formation in VA RNAI plasmid
transfected cells. For this experiment, HEK293 cells were trans-
fected with plasmids expressing VA RNAI from HAdV-4, HAdV-5,
HAdV-12 and HAdV-37. After 24 hpt cells were infected with the
dl705 virus. The infected cells were harvested at 40 hpi, total cell
lysate prepared and titrated in 911 cells. As shown in Fig. 7D,
ectopic expression of the HAdV-4 and HAdV-37 VA RNAI were
most effective in rescuing dl705 virus production. In contrast,
HAdV-12 VA RNAI functioned poorly in all assays tested (Fig. 7).
Discussion
Here we have analyzed the ability of various RNAi and IFN
suppressor proteins and serotype-speciﬁc VA RNAI to complement
growth of HAdV dl705, a virus mutant defective in VA RNAI
expression. Previous reports have shown that transient overex-
pression of the P19, NS3, VP35 and E3L proteins can suppress
induced RNAi directed against reporter gene constructs in mam-
malian cells (Dunoyer et al., 2004; Haasnoot et al., 2007; Liu et al.,
2012; Schnettler et al., 2008; Zhu et al., 2012). In addition, VP35,
E3L and NS3 can complement the RNAi suppressor function of the
HIV-1 Tat protein to support HIV-1 replication (Haasnoot et al.,
2007; Schnettler et al., 2009). Since HAdV VA RNAI exhibits both
IFN and RNAi suppressor activity (reviewed in Punga et al. (2013)),
we tested whether transient overexpression of the P19, NS3, VP35,
E3L proteins could substitute for VA RNAI in supporting dl705
virus replication. Plant virus proteins P19 and NS3, which lack IFN
antagonistic activity (Schnettler et al., 2009), failed to complement
dl705 virus growth whereas the VACV E3L protein showed a
stimulatory effect on dl705 replication. Unexpectedly, the EBOV
VP35 protein, which appears to use a similar strategy as the VACV
E3L protein to counteract the antiviral IFN response (Feng et al.,
2007; Schumann et al., 2009), failed to enhance viral capsid
protein accumulation in dl705-infected cells.
Previous reports have shown that the E3L protein exhibits a
dual inhibitory effect on PKR activity. Thus, a direct binding of PKR
to the E3L N-terminal domain or a sequestration of dsRNA by the
E3L C-terminal domain blocks PKR functions in different experi-
mental systems (Chang and Jacobs, 1993; Romano et al., 1998;
Sharp et al., 1998). Our biochemical analysis suggests that the E3L
C-terminal region containing the dsRNA-binding domain, and not
the N-terminal PKR binding domain, is needed to enhance dl705
replication (Fig. 2). The E3L dsRNA-domain binds and thereby
sequesters dsRNAs (Chang and Jacobs, 1993) needed for PKR
activation. Thus, it is likely that the E3L protein blocks PKR
activation in dl705-infected cells by sequestering the HAdV
dsRNAs produced during a lytic infection (Maran and Mathews,
1988). It is important to mention that despite of our efforts, we
were unable to express the E3L protein containing only the
C-terminal dsRNA-binding domain (amino acids 100–190) in
Fig. 3. The VACV E3L protein functionally substitutes for VA RNAI in new virus
progeny formation. dl705 virus titer (FFU/ml) was determined in 911 cells after re-
infection with HEK293 cell lysates transfected with indicated plasmids (4 μg of
plasmid DNA) and infected with dl705 virus. Hyphen (-) indicates transfection with
an empty plasmid (pcDNA3.1). Bars denote the mean virus titer (log 10)7standard
deviation of the means.
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Fig. 4. Adenovirus dl705 infection alters E3L subcellular distribution. (A) HeLa cells were transfected with 1 μg of E3L(wt)-Flag encoding plasmid followed by dl705 infection
before the cells were subjected to indirect immunoﬂuorescence analysis. The Flag-tagged E3L(wt) protein (red) and adenovirus E2-72K protein (green) were simultaneously
stained and visualized. Nuclei were counterstained with DAPI (blue). Scale bars correspond to 10 μm. (B) Subcellular fractionation of dl705-infected and E3L(wt)-Flag
expressing HeLa cells. Total (T), cytoplasmic (C) and nuclear (N) protein extracts were analyzed by western blotting. Detection of the Lamin B1 and GAPDH proteins was used
to evaluate the efﬁciency of cytoplasmic and nuclear protein extraction. Detection of the c-Myc protein serves as control for MG132 treatment. The E3L protein was detected
with an anti-Flag antibody. MG132 treatment (25 μM) was done 6 h before the cells were harvested. Relative accumulation of the Flag-tagged E3L protein in respective
subcellular fractions is shown as the ratio to the total E3L protein. The Flag-tagged E3L signal in total lysates was considered as 1.
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HEK293 cells. The reason for this failure remains unresolved, but
considering also that the E3L(KRAA) protein showed reduced
accumulation in the same cell line (Fig. 2B), it is possible that
DNA sequence manipulations around the E3L C-terminal domain
affect overall stability of the E3L protein.
The E3L protein expression enhances dl705 capsid protein
accumulation, which coincides with a detectable reduction in
eIF2α Ser51 phosphorylation (Fig. 2C). This change in phosphor-
ylation was similar in cells expressing the VA RNAs, suggesting
that both VA RNA and the E3L protein affect eIF2α Ser51 phos-
phorylation to a similar extent in dl705 infected HEK293 cells.
Despite this the E3L protein did not enhance dl705 virus replica-
tion to the same magnitude as did the ectopic expression of the
HAdV-2 VA RNAs (pHindB, Fig. 3). A quantiﬁcation of 35S-labeled
hexon protein synthesis indicated that VA RNA co-expression
increased hexon protein levels up to 4-fold better compared to
cells expressing the E3L(wt) protein (Fig. 2B). This observation
indicated that the effect of the VA RNAs on capsid protein
synthesis and virus progeny formation in HEK293 cells might
not only be due to a diminution in eIF2α Ser51 phosphorylation.
Indeed, a quantitative analysis of hexon mRNA levels indicated
that ectopic VA RNA expression increased hexon mRNA abundance
in dl705-infected HEK293 cells, an effect not seen with the E3L
protein (Fig. 6). Thus, VA RNA, in contrast to E3L, appears to have
two alternative mechanisms to stimulate HAdV growth; ﬁrst VA
RNA, like the E3L protein, rescues translation by reducing eIF2α
phosphorylation; second, the VA RNAs have a positive effect on
viral late mRNA accumulation not seen with the E3L protein.
Although the mechanism by which the VA RNAs enhance mRNA
abundance is not known the effect has been reported previously.
Thus, it has been demonstrated that transfection of a VA RNA
expressing plasmid increases the steady state cytoplasmic mRNA
abundance in HEK293 cells (Strijker et al., 1989; Svensson and
Fig. 6. The E3L protein does not increase hexon mRNA levels in dl705-infected
cells. HEK293 cells, transfected with E3L(wt) or VA RNA (pHindB) expressing
plasmids (2 and 4 μg), were infected with the dl705 virus for 24 h. Viral hexon and
housekeeping HRPT1 mRNA levels were detected by qRT-PCR and hexon mRNA
levels were normalized to HRPT1 mRNA levels. Hexon mRNA from the cells infected
solely with dl705 was set as 1. Bars denote the mean7standard deviation of a
triplicate experiment.
Fig. 5. E3L enhances adenovirus capsid protein synthesis by suppressing PKR
phosphorylation of eIF2α. (A) PKR positive (HeLakd-con) and PKR negative (HeLakd)
cells were transfected with 4 μg of E3L(wt) or VA RNA (pHindB) expressing
plasmids followed by dl705 infection and 35S-metabolic labeling. Expression of
PKR, Flag-tagged E3L(wt) and actin proteins in total cell lysates was detected by
western blot analysis (WB) using the respective antibodies. The viral capsid
proteins were detected by autoradiography (35S). Asterisk (n) indicates the migra-
tion of viral hexon protein. The 35S labeled hexon protein signals were quantiﬁed
and relative signal intensities are shown below the image. (B) Expression of the E3L
(wt) protein speciﬁcally reduces eIF2α Ser51 phosphorylation in HeLakd-con cells.
Total protein samples from HeLakd-con and HeLakd cells were analyzed by western
blotting using anti-eIF2α (Total) and anti-eIF2α (P-Ser51) antibodies. Relative
accumulation of P-Ser51 signal in total eIF2α protein pool (P-Ser51/Total) is shown.
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Fig. 7. Complementation of dl705 virus replication by serotype-speciﬁc VA RNAI. (A) HAdV-4 and HAdV-37 VA RNAI enhance the viral capsid protein production in dl705-
infected cells. Four micrograms of plasmids encoding VA RNAI from HAdV-4, HAdV-5, HAdV-12, HAdV-37 serotypes were transfected into HEK293 cells followed by dl705
infection and metabolic labeling. Total protein samples were analyzed by western blotting (WB) and autoradiography (35S). Hyphen (-) indicates uninfected sample or a
sample transfected with an empty (pcDNA3.1) plasmid. As the control, cells were also infected with the wild type HAdV-5 (dl703) virus. Asterisk (n) indicates migration of
the viral hexon protein. Relative quantiﬁcation of 35S-labeled hexon protein is shown below the image. (B) Transient expression of serotype-speciﬁc VA RNAI. Total RNA was
extracted from the HEK293 cells, which underwent the same experimental setup as in (A). Isolated RNA was analyzed by Northern blotting using γ-32P-ATP labeled probes
against VA RNAI, VA RNAII, U6 snRNA. (C) The same protein lysates as shown in (A) were analyzed by western blotting using anti-eIF2α (Total) and anti-eIF2α (P-Ser51)
antibodies. Relative accumulation of P-Ser51 signal in total eIF2α protein pool (P-Ser51/Total) is shown. The P-Ser51/Total eIF2α ratio in dl705 only infected sample was set as
1. (D) Improved formation of dl705 virus particles in serotype-speciﬁc VA RNAI expressing cells. Virus titers (FFU/ml) were determined in 911 cells after re-infection with
HEK293 cell lysates transfected with indicated plasmids and infected with dl705 virus. Bars denote the mean virus titer (log10)7standard deviation of the means.
Akusjarvi, 1990). The mechanism has not been thoroughly inves-
tigated although one of the original reports proposed that VA RNAI
might stabilize ribosome bound mRNAs (Strijker et al., 1989),
whereas the other concluded that the effect was mRNA length
dependent (Svensson and Akusjarvi, 1990).
Interestingly, our results also demonstrated that HAdV-4 and
HAdV-37 VA RNAI rescued dl705 growth more efﬁciently com-
pared to the native HAdV-5 VA RNAI (Fig. 7D). Improved dl705
replication in HAdV-4 and HAdV-37 VA RNAI co-transfected cells
was also accompanied by a reduction in eIF2α Ser51 phosphoryla-
tion (Fig. 7C). However, the difference in eIF2α Ser51 phosphor-
ylation between the serotype-speciﬁc VA RNAs was not dramatic,
implying that other activities coupled to VA RNAI, like the mRNA
enhancer function, might contribute to the serotype-speciﬁc
differences in VA RNAI function. A clear outlier among the tested
VA RNAs was HAdV-12 VA RNAI, which was efﬁciently expressed
(Fig. 7B), but did not enhance dl705 virus growth in HEK293 cells
(Fig. 7D). This observation is in line with a recent report demon-
strating that the HAdV-12 VA RNAI is a poor inhibitor of PKR
activation in A549 cells (Wu et al., 2015).
A recent report showed that the HAdV-5 E1B-55K and E4orf6
proteins block activation of the PKR protein and maintain low
levels of eIF2α Ser51 phosphorylation in virus-infected cells
(Spurgeon and Ornelles, 2009). The Cul5-based ubiquitin ligase
activity associated with the E1B-55 K/E4orf6 protein complex
appeared to be necessary to prevent activation of PKR and
phosphorylation of eIF2α during the late phase of HAdV-5 infec-
tion. However, the expression of the E1B-55K and E4orf6 proteins
did not promote the cytoplasmic accumulation of VA RNAI and VA
RNAII in these experiments (Spurgeon and Ornelles, 2009). Hence,
it is possible that the eIF2α Ser51 phosphorylation is rigorously
controlled by the expression and activity of several virus-encoded
factors (E1B-55K, E4orf6, VA RNAI) during different phases of the
HAdV infection.
Collectively, our results suggest that the VA RNAI-mediated
suppression of the IFN-induced PKR pathway is more critical for
support of virus multiplication compared to the RNAi suppressor
activity associated with the VA RNAs. In contrast to our ﬁndings
(Fig. 1), a recent report has suggested that the TBSV P19 protein
can complement the RNAi suppressor function of the VA RNAs and
stimulate VA RNA mutant virus growth (Rauschhuber et al., 2013).
Our results do not exclude the RNAi suppressing function of the VA
RNAs as a mechanism supporting virus growth (Andersson et al.,
2005). However, our data clearly favor the conclusion whereby the
main target for VA RNAI intervention is the IFN-induced PKR
system. This is further supported by a report showing that PKR
knockdown, but not Dicer knockdown, rescued growth of a VA
RNA deﬁcient virus (Kamel et al., 2013). In addition, inhibition of
PKR activity with the serine-kinase inhibitor 2-aminopurine also
functionally substitutes for VA RNAI (Cascallo et al., 2003).
Taken together, our data strongly suggest that the cellular IFN
system is the major antiviral response that the adenovirus has to
handle, and that its suppression is one of main functions of the VA
RNAI, at least in the cell lines tested.
Materials and methods
Plasmids
The original plasmids containing TBSV P19, RHBV NS3, EBOV
VP35, VACV E3L cDNA sequences were kindly provided by Dr. Ben
Berkhout (Haasnoot et al., 2007; Schnettler et al., 2009). The
corresponding cDNAs were cloned into pcDNA3.1 (Invitrogen)
vector containing a Flag epitope tag sequence. The constructed
plasmids express the P19, NS3, E3L and VP35 proteins as C-
terminal Flag-tagged fusion proteins in mammalian cells. The
plasmids encoding for the Flag-tagged E3L(KRAA) and E3L(1–
100) proteins were generated using QuikChange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies) and by deletion
PCR, respectively. The pHindB plasmid, which expresses HAdV-2
VA RNAI and VA RNAII, has been described previously (Svensson
and Akusjarvi, 1984). The plasmids expressing VA RNAI from
HAdV-4, HAdV-5, HAdV-12 and HAdV-37 serotypes were gener-
ated by PCR ampliﬁcation of the respective viral DNA sequences
and cloned into pcDNA5/FRT (Invitrogen) plasmid.
Cell lines, transfections and virus infections
Human embryonic kidney cell line 293 (HEK293) (Graham
et al., 1977), human epithelial cervix carcinoma cell line (HeLa),
and human embryonic retina cell line 911 (911) (Fallaux et al.,
1996) were grown as monolayers in growth media containing
Dulbecco's modiﬁed Eagle medium (DMEM, Invitrogen), 10% fetal
calf serum (FCS, PAA), 100 U/ml penicillin, 100 U/ml streptomycin
(PEST, Gibco) at 37 1C in 7% CO2 containing cell incubator. HeLa
PKRkd and PKRkd-con cell lines were kindly provided by Dr. Charles
Samuel (Zhang and Samuel, 2007) and were maintained in growth
media supplemented with 1 μg/ml puromycin (Sigma). Approxi-
mately 24 h before transfection cells were seeded in 60 mm plates
to reach a conﬂuence of 60–70% at the time of transfection.
Transient transfections were performed using TurboFect transfec-
tion reagent (Thermo Scientiﬁc) according to the manufacturer's
instructions. Transfected cells were further infected with dl703 or
dl705 viruses 24 h post-transfection (hpt). The dl703 and dl705
viruses are derivatives of HAdV-5 where the VA RNA region was
deleted and replaced with the corresponding region from HAdV-2.
The wild-type virus (dl703) contains both VA RNAI and VA RNAII
from HAdV-2 whereas the VA RNAI deﬁcient virus (dl705) con-
tains a deletion in the Box B element inactivating VA RNAI
expression (Bhat and Thimmappaya, 1984). As the HAdV-2 and
HAdV-5 genomes are closely related, the VA RNA sequences from
both serotypes are almost identical (Ma and Mathews, 1996). Cells
were infected at a multiplicity of 5 ﬂuorescence forming units
(FFU) per cell in 1 ml of infection media (DMEMþ2% NCSþPEST)
for 1 h at 37 1C. After 1 h of incubation the cells were washed twice
with the growth media and replaced with fresh growth media for
further incubation for 24 h.
35S-methionine/cysteine metabolic labeling
Approximately 22 h post-infection (hpi), the growth medium
was removed, the cells washed once with PBS, and incubated in
methionine/cysteine-free DMEM depletion media (Invitrogen),
supplemented with 10% FCS, 1% PEST and 2% glutamine, for
30 min. After the depletion period, the cells were incubated in
depletion media complemented with [35S] methionine/cysteine
mix (30 mCi/ml; 2 ml/plate) for 2 h. After the pulse-labeling, cells
were washed twice in PBS, collected into microcentrifuge tubes
and processed as described below.
Total cell lysates and cell fractionation
Total cell lysates were prepared by incubating the collected cell
pellets in RIPA buffer (25 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1%
NP-40, 1% sodium deoxycholate, 0.1% SDS, supplemented with
protease inhibitor (Complete Mini EDTA-free, Roche Applied
Sciences)) on ice for 15 min. The protein extract was clariﬁed by
centrifugation for 15 min and the protein concentration was
determined by the Bradford assay (Bio-Rad). Cell fractionation
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experiments were carried out using the PARIS™ kit (Life Technol-
ogies) according to the manufacture's instructions.
SDS-PAGE and western blotting
Equal concentrations of protein samples were separated on a
4–20% gradient precast (Bio-Rad) or on home-made 14% SDS-PAGE
gels. Proteins were transferred onto Immobilon-FL western blot
nitrocellulose membrane (Millipore) using Towbin transfer buffer
(25 mM Tris, 192 mM Glycine). The membrane was blocked with
Odyssey blocking buffer (LI-COR) for 1 h at room temperature and
thereafter incubated with the primary antibody overnight at 4 1C.
Next, the membrane was washed with PBST (PBSþ0.05% Tween
20) and incubated with the ﬂuorescent secondary antibody
(IRDyes, LI-COR) for 45 min at room temperature. The PBST
washed membranes were scanned with the Odyssey scanner (LI-
COR). Scanned western blot images were quantiﬁed using Image
Studio 2.1TM Software (LI-COR) according to the manufacture's
instructions. The following primary antibodies were used: anti-
lamin B1 (1:4000; Abcam, ab16048), anti-Ad5 capsid (1:5000;
Abcam, ab6982), anti-Flag (1:1000, Sigma, M2, F1804), anti-c-Myc
(1:1000; Santa Cruz, sc-42), anti-actin (1:1000; Santa Cruz, sc-
1616), anti-GAPDH (1:50,000; Ambion, Am4300), anti-eIF2 (1:500,
Abcam, ab26197), anti-eIF2(phospho-S51) (1:500, Abcam,
ab32157), anti-PKR (1:1000, Santa Cruz, sc-707). After immuno-
blotting the western blot membranes were exposed to a Phos-
phorImager screen (Fuji) and the 35S-signals quantitated using the
Image One software (Bio-Rad).
RNA extraction, northern blot analysis and qRT-PCR
Total RNA was extracted using the TRIreagent (Sigma) as
previously described (Inturi et al., 2013). Ten micrograms of total
RNA was separated on a denaturing 12% polyacrylamide gel,
transferred to a Hybond NX membrane (Amersham Biosciences).
The γ-32P–ATP labeled probes were hybridized to the membrane
as described previously (Kamel et al., 2014). After overnight
hybridization in ULTRAhybs buffer (Ambion), the membrane was
washed three times for 10 min at 42 1C in 3 SSC, 0.5% SDS buffer
followed by a single wash with 1 SSC, 0.5% SDS buffer for 15 min
at 42 1C. Radioactive signals were detected and analyzed as
described above. cDNA synthesis from total RNA samples was
performed as published previously (Inturi et al., 2013). Puriﬁed
RNA was DNaseI (RapidOut DNA Removal Kit; Thermo Scientiﬁc)
treated to remove genomic DNA from the RNA preparations. RNA
expression was analyzed by quantitative reverse transcription PCR
(qRT-PCR) on an Applied Biosystems 7900 system (Life Technolo-
gies) using HOT FIREPols EvaGreens qPCR Supermix (Solis
BioDyne). The HRPT1 primer sequences were obtained from
RTPrimerDB database (http://medgen.ugent.be/rtprimerdb/), whe-
reas hexon primer sequences were published previously (Inturi
et al., 2013). Relative hexon mRNA expression was calculated after
normalization to the HRPT1 mRNA levels using 2ΔΔCT method
(Schmittgen and Livak, 2008).
Indirect immunoﬂuorescence assay
The indirect immunoﬂuorescence assay was carried out as
previously described (Inturi et al., 2013). Brieﬂy, HeLa cells were
grown on ﬁbronectin coated coverslips and transfected for 24 h
with the indicated plasmids. Thereafter, the cells were infected
with dl705 virus (5 FFU/cell) or mock infected (infection media
without virus) for 1 h. Cells were ﬁxed 24 hpi with 3% parafor-
maldehyde in PBS for 15 min and permeabilized with 0.1% Triton
X-100 in PBST (PBSþ0.01% Tween 20) for 15 min at room tem-
perature. After blocking the cells with 2% BSA/PBST solution, the
coverslips were subjected to immunoﬂuorescence analysis using
anti-Flag (M2, Sigma, 1:1000) and anti-E2A-72 K (kindly provided
by Bruce Stillman) antibodies. Proteins were visualized with
anti-FITC-conjugated anti-rabbit IgG (Sigma, F6005, 1:1000) and
anti-TRITC-conjugated anti-mouse IgG (Sigma, T5393, 1:1000)
secondary antibodies. Nucleus was detected by DAPI staining
supplemented into the Fluoromount-G mounting media (Southern
Biotech). Immunolabeled cells were visualized under a ﬂuores-
cence microscope (Nikon eclipse 90i) and the images were
analyzed with the NIS-elements (AR 3.10, Nikon) software.
Virus titration
HEK293 cells were transfected with respective plasmids fol-
lowed by dl705 virus infection. Infected cells were harvested
40 hpi when the cells showed a clear cytopathic effect. Cell pellets
were resuspended in 0.1 M Tris–HCl, pH 8.0, freeze-thawed three
times, and the cell debris was removed by centrifugation. The virus
containing supernatants were serially diluted 10-fold from 1:102
to 1:108 in growth media. An aliquot (100 μl) of each dilution was
transferred to conﬂuent monolayers of 911 cells seeded on 35 mm
culture dishes. The infected 911 cells were incubated for an
additional 36 h at 37 1C in a cell incubator. Thereafter, the infected
911 cells were extensively washed with PBS and ﬁxed with 3 ml
95% methanol in PBS for 15 min at room temperature. After
ﬁxation, the cells were incubated with anti-adenovirus antibody
(Millipore, MAB8052, 1:500) for 30 min at room temperature. The
cells were washed with PBS before incubation with anti-FITC-
conjugated anti-mouse IgG antibody (Sigma, F9006, 1:100) for
30 min at room temperature. Next, the cells were extensively
washed in PBS and the positively stained cells were counted under
a ﬂuorescence microscope (Nikon eclipse 90i). The endpoint virus
titers (FFU/ml) were set at the last dilution giving unequivocal
ﬂuorescent signal. The virus titers represent the mean7SD of two
independent experiments assayed in triplicate.
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